THE US Food and Drug Administration has approved GlaxoSmithKline's Shingrix shingles vaccine, indicated for the prevention of herpes zoster in adults aged 50 years and older.
The vaccine is also currently under review for approval in the EU, Japan and Australia.
GSK Vaccines chief medical officer Thomas Breuer said Shingrix had been "developed specifically to overcome the age-related decline in immunity".
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Oct 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Oct 17